Plasmodium falciparum CS C-terminal fragment: preclinical evaluation and phase I clinical studies

Details

Serval ID
serval:BIB_0E665AE0E84D
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Plasmodium falciparum CS C-terminal fragment: preclinical evaluation and phase I clinical studies
Journal
Parassitologia
Author(s)
Roggero  M. A., Weilenmann  C., Bonelo  A., Audran  R., Renggli  J., Spertini  F., Corradin  G., Lopez  J. A.
ISSN
0048-2951 (Print)
Publication state
Published
Issued date
09/1999
Volume
41
Number
1-3
Pages
421-4
Notes
Journal Article
Research Support, Non-U.S. Gov't
Review --- Old month value: Sep
Abstract
Preclinical evaluation of synthetic peptides corresponding to the C-terminal regions of the circumsporozoite (CS) protein in various Plasmodia showed that these preparations were immunogenic and safe upon injection in various animal models. Additionally, the corresponding peptide from Plasmodium falciparum was widely recognized by sera and PBL obtained from semi-immune adults living in malaria endemic areas. Moreover, the CS C-terminal peptide derived from P. berghei conferred protection upon challenge with live sporozoites in mice. A GLP preparation of the synthetic peptide corresponding to residues 282-383 of the Pf CS, NF-54 strain is currently evaluated in a open, non-randomized, Phase I human trial. Data obtained after the second antigen injection show that the malaria vaccine Pf CS 282-383 is safe, well tolerated and gives rise to high antibody titre, CD4+ and CD8+ lymphocyte responses.
Keywords
Adult Animals Antigens, Protozoan/*immunology Clinical Trials, Phase I Humans *Malaria Vaccines Mice Peptide Fragments/*immunology Plasmodium berghei/immunology Plasmodium falciparum/*immunology Protozoan Proteins/chemistry/*immunology
Pubmed
Create date
24/01/2008 15:55
Last modification date
20/08/2019 13:35
Usage data